AEs by maximum grade in the LTE period
AEs, n (%) . | All-Cause AEs (n = 16)∗ . | Treatment-related AEs (n = 16) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
All grades . | Grade 1 . | Grade 2 . | Grade 3† . | Grade 4 . | All grades . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
Patient with ≥1 AE | 13 (81) | 12 (75) | 7 (44) | 2 (13) | 2 (13) | 3 (19) | 2 (13) | 2 (13) | 0 | 0 |
Upper respiratory tract infection | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Rhinorrhea | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Vulvovaginal dryness | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Cough | 1 (6) | 1 (6) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
Diarrhea | 2 (13) | 2 (13) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
Back pain | 3 (19) | 3 (19) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Arthralgia | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Rash | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COVID-19 | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Pneumonia | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Thrombocytosis | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Migraine | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Pulmonary embolism | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Hypertension | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
COVID-19 pneumonia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
Thrombocytopenia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
AEs, n (%) . | All-Cause AEs (n = 16)∗ . | Treatment-related AEs (n = 16) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
All grades . | Grade 1 . | Grade 2 . | Grade 3† . | Grade 4 . | All grades . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
Patient with ≥1 AE | 13 (81) | 12 (75) | 7 (44) | 2 (13) | 2 (13) | 3 (19) | 2 (13) | 2 (13) | 0 | 0 |
Upper respiratory tract infection | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Rhinorrhea | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Vulvovaginal dryness | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
Cough | 1 (6) | 1 (6) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
Diarrhea | 2 (13) | 2 (13) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
Back pain | 3 (19) | 3 (19) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Arthralgia | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Rash | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COVID-19 | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Pneumonia | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Thrombocytosis | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Migraine | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Pulmonary embolism | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
Hypertension | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
COVID-19 pneumonia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
Thrombocytopenia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
Includes treatment-related AEs occurring in ≥1 patient and all-cause AEs for ≥2 patients or any that were grade 3 or 4.
Grade 3 AEs due to any cause occurred in 2 patients including 1 case each of COVID-19, thrombocytosis, migraine, and pulmonary embolism in 1 patient and hypertension in a second patient.